Karyopharm Therapeutics Inc. (KPTI) announced its preliminary revenue estimates for the fourth quarter and the full year of 2024 on Monday. The company anticipates total revenue, which includes income from licenses and royalties from partners, will reach approximately $30 million in the fourth quarter of 2024 and about $145 million for the entire year.
For its product, U.S. XPOVIO, net product revenue is expected to be around $29 million in the fourth quarter and approximately $113 million for the full year 2024.
In addition, Karyopharm revealed the appointment of Lori Macomber as the Executive Vice President, Chief Financial Officer, and Treasurer, with her tenure commencing on January 3, 2025.
"Our primary strategic focus for 2025 is to capitalize on the transformative potential to revolutionize the standard of care in myelofibrosis, with pivotal results from our Phase 3 SENTRY trial anticipated in the latter half of this year," stated Richard Paulson, the President and Chief Executive Officer of Karyopharm. "Our teams are steadfastly committed to executing high-caliber clinical trials, engaging with investigators, and ensuring diligent patient enrollment within the first half of the year. We are enthusiastic about the prospects of selinexor becoming the first all-oral combination therapy for myelofibrosis and the positive outcomes it could offer to the patient community. We are eager to present our top-line data and are actively preparing for a swift market launch, harnessing our proven commercialization strengths."
The material has been provided by InstaForex Company - www.instaforex.com
For its product, U.S. XPOVIO, net product revenue is expected to be around $29 million in the fourth quarter and approximately $113 million for the full year 2024.
In addition, Karyopharm revealed the appointment of Lori Macomber as the Executive Vice President, Chief Financial Officer, and Treasurer, with her tenure commencing on January 3, 2025.
"Our primary strategic focus for 2025 is to capitalize on the transformative potential to revolutionize the standard of care in myelofibrosis, with pivotal results from our Phase 3 SENTRY trial anticipated in the latter half of this year," stated Richard Paulson, the President and Chief Executive Officer of Karyopharm. "Our teams are steadfastly committed to executing high-caliber clinical trials, engaging with investigators, and ensuring diligent patient enrollment within the first half of the year. We are enthusiastic about the prospects of selinexor becoming the first all-oral combination therapy for myelofibrosis and the positive outcomes it could offer to the patient community. We are eager to present our top-line data and are actively preparing for a swift market launch, harnessing our proven commercialization strengths."
The material has been provided by InstaForex Company - www.instaforex.com